Human fibrinogen (Shanxi Kangbao Biological Product Co. Ltd.)

Primary objectives: (1) To evaluate the pharmacokinetic characteristics of a single dose of Conbo human fibrinogen in patients with congenital fibrinogen deficiency or deficiency; (2) To evaluate the effectiveness of Conbo human fibrinogen in treating bleeding events in patients with congenital fibrinogen deficiency or deficiency. Secondary objectives: (1) To evaluate the safety of Conbo human fibrinogen in treating bleeding events in patients with congenital fibrinogen deficiency or deficiency; (2) To evaluate the pharmacokinetic characteristics of a single dose of similar products already on the market in patients with congenital fibrinogen deficiency or deficiency.